{
 "as_of": "2026-11-06",
 "cmr": "fi-cm-kg/FSME/FI4000087861",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Herantis Pharma Oyj (First North Finland: FI4000087861) — research page\n\nAs of 2026-11-06 · fi-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Herantis Pharma Oyj, listed on First North Finland under ticker FI4000087861, with ISIN FI4000087861 and LEI 743700W4CQVYAT3WKK38. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 31 filings on 27 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 8.5 days. The latest filing is dated 2026-11-05, one day before the record date of 2026-11-06, and is of type Investor News. The First North Finland exchange median is 7.0 days cadence, 39.5 filings and 9.0 days latency across 48 issuers. The sector median is not on the record.\n\n## Auditor\n\nThe auditor and its location are not on the record. The auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories. The rule version is acm-68000/fi/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 2 research houses: Edison Group and Inderes.\n\n## Open research\n\nThe record holds 5 openly published research notes: Redeye, 2023-01-31; ABG Sundal Collier, 2021-02-09; Edison Investment Research, 2020-04-02; ABG Sundal Collier, 2020-02-25; and ABG Sundal Collier, 2020-02-04.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.\n\n## Sources\n\n11 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mcp.fi-cm-kg.ai/events/FSME/FI4000087861 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterHEX|FirstNorthInformationHEX (the halt flag)\n- https://fi.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://herantis.com/investors/analyst-coverage/ (coverage)\n- https://herantis.com/wp-content/uploads/2023/02/Redeye-equity-research-update-January-of-Herantis-2023-English.pdf (open research)\n- https://herantis.com/wp-content/uploads/2021/02/ABG-in-depth-research-February-9.pdf (open research)\n- https://herantis.com/wp-content/uploads/2020/04/Herantis-Pharma-Funded-to-key-data-inflection-points.pdf (open research)\n- https://herantis.com/wp-content/uploads/2020/04/ABG_Impressions_from_capital_markets_day_2020-03-25.pdf (open research)\n- https://herantis.com/wp-content/uploads/2020/02/ABG_Herantis_Initiation_2020-02-04.pdf (open research)\n- https://mcp.fi-cm-kg.ai/record/FSME/FI4000087861 (the record)\n",
 "market": "FI",
 "node": "fi-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the FI vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "FI",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "FI",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "FI",
    "state": "not_on_record"
   },
   "changes": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "fi-cm-kg/FSME/FI4000087861",
  "coverage": {
   "count": 2,
   "houses": [
    {
     "house": "Edison Group",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Antti Siltanen",
     "house": "Inderes",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/investors/analyst-coverage/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://herantis.com/investors/analyst-coverage/",
     "result": "read: 2 of 4 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 48,
     "median_cadence_gap_days": 7,
     "median_filings": 39.5,
     "median_latency_days": 9,
     "name": "First North Finland"
    },
    "sector": {
     "market": "FI",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual financial report": 1,
    "Decisions of general meeting": 1,
    "Financial calendar": 1,
    "Financial statement release": 1,
    "Half year financial report": 1,
    "Inside information": 3,
    "Investor News": 9,
    "Major shareholder announcements": 2,
    "Managers' Transactions": 6,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 3,
    "Total number of voting rights and capital": 2
   },
   "cadence_median_gap_days": 8.5,
   "filing_days": 27,
   "filings": 31,
   "latency_days": 1,
   "latest": [
    {
     "category": "Investor News",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b2db633e5959b1739d65f8a58d29ba920&lang=en&src=listed",
     "title": "Herantis Pharma: newly published clinical evidence validates HER-096 Phase 2 study design",
     "type": "Investor News"
    },
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-10-28",
     "source": "https://view.news.eu.nasdaq.com/view?id=b0aeadba5f41c8247b4d145a501d02ac4&lang=en&src=listed",
     "title": "Composition of Herantis Pharma Plc's Shareholders' Nomination Committee",
     "type": "Other information disclosed according to the rules of the Exchange"
    },
    {
     "category": "Half year financial report",
     "date": "2026-08-20",
     "source": "https://view.news.eu.nasdaq.com/view?id=b9e18ce445b6220a8ea4f0fcbae65b316&lang=en&src=listed",
     "title": "Herantis Pharma releases 1H 2026 report today",
     "type": "Half year financial report"
    },
    {
     "category": "Investor News",
     "date": "2026-08-10",
     "source": "https://view.news.eu.nasdaq.com/view?id=bb4c892e4639e838b9754ec3532827aa4&lang=en&src=listed",
     "title": "Herantis Pharma to publish financial statements for the first half of 2026 on August 20, 2026 - invitation to webcast presentation",
     "type": "Investor News"
    },
    {
     "category": "Major shareholder announcements",
     "date": "2026-07-31",
     "source": "https://view.news.eu.nasdaq.com/view?id=b6140ec9a489e39091f786143f4d71202&lang=en&src=listed",
     "title": "Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act",
     "type": "Major shareholder announcements"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.fi-cm-kg.ai/events/FSME/FI4000087861",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "eu-sources/fi/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "First North Finland"
   },
   "isin": {
    "read_by": "eu-sources/fi/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "FI4000087861"
   },
   "jurisdiction": {
    "market": "FI",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "eu-sources/fi/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "filled",
    "value": "743700W4CQVYAT3WKK38"
   },
   "name": {
    "read_by": "eu-sources/fi/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Herantis Pharma Oyj"
   },
   "sector": {
    "market": "FI",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "FI",
    "state": "not_on_record"
   },
   "segment": {
    "market": "FI",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "eu-sources/fi/roster.py (FIRDS https://registers.esma.europa.eu/solr/esma_registers_firds_files/select)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "FI4000087861"
   },
   "website": {
    "market": "FI",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "FI",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "FI",
  "node": "fi-cm-kg",
  "numbers_hash": "sha256:f751e6df23c92e53e9c3e2e7f00dbd4d0bded5a240134fd65f87479760128a88",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2023-01-31",
     "kind": "independent",
     "publisher": "Redeye",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/wp-content/uploads/2023/02/Redeye-equity-research-update-January-of-Herantis-2023-English.pdf",
     "state": "sourced",
     "title": "Redeye equity research update January of Herantis 2023"
    },
    {
     "date": "2021-02-09",
     "kind": "independent",
     "publisher": "ABG Sundal Collier",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/wp-content/uploads/2021/02/ABG-in-depth-research-February-9.pdf",
     "state": "sourced",
     "title": "Herantis Pharma"
    },
    {
     "date": "2020-04-02",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/wp-content/uploads/2020/04/Herantis-Pharma-Funded-to-key-data-inflection-points.pdf",
     "state": "sourced",
     "title": "Funded to key data inflection points"
    },
    {
     "date": "2020-02-25",
     "kind": "independent",
     "publisher": "ABG Sundal Collier",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/wp-content/uploads/2020/04/ABG_Impressions_from_capital_markets_day_2020-03-25.pdf",
     "state": "sourced",
     "title": "Herantis Pharma"
    },
    {
     "date": "2020-02-04",
     "kind": "issuer-sponsored",
     "publisher": "ABG Sundal Collier",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://herantis.com/wp-content/uploads/2020/02/ABG_Herantis_Initiation_2020-02-04.pdf",
     "state": "sourced",
     "title": "Herantis Pharma"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://fi.eu-cm-kg.ai/book/aio.json",
    "door": "https://fi.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/fi/mifid-ii-product-governance/r1",
   "section": "fi.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.fi-cm-kg.ai/record/FSME/FI4000087861",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterHEX|FirstNorthInformationHEX",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:f751e6df23c92e53e9c3e2e7f00dbd4d0bded5a240134fd65f87479760128a88",
 "path": "/fi/FSME/FI4000087861",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Herantis Pharma Oyj, listed on First North Finland under ticker FI4000087861, with ISIN FI4000087861 and LEI 743700W4CQVYAT3WKK38. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 31 filings on 27 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 8.5 days. The latest filing is dated 2026-11-05, one day before the record date of 2026-11-06, and is of type Investor News. The First North Finland exchange median is 7.0 days cadence, 39.5 filings and 9.0 days latency across 48 issuers. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor and its location are not on the record. The auditor changes are not on the record, as this register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories. The rule version is acm-68000/fi/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 2 research houses: Edison Group and Inderes.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds 5 openly published research notes: Redeye, 2023-01-31; ABG Sundal Collier, 2021-02-09; Edison Investment Research, 2020-04-02; ABG Sundal Collier, 2020-02-25; and ABG Sundal Collier, 2020-02-04.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "11 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.fi-cm-kg.ai/events/FSME/FI4000087861"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterHEX|FirstNorthInformationHEX"
  },
  {
   "for": "the orderability chapter",
   "source": "https://fi.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://herantis.com/investors/analyst-coverage/"
  },
  {
   "for": "open research",
   "source": "https://herantis.com/wp-content/uploads/2023/02/Redeye-equity-research-update-January-of-Herantis-2023-English.pdf"
  },
  {
   "for": "open research",
   "source": "https://herantis.com/wp-content/uploads/2021/02/ABG-in-depth-research-February-9.pdf"
  },
  {
   "for": "open research",
   "source": "https://herantis.com/wp-content/uploads/2020/04/Herantis-Pharma-Funded-to-key-data-inflection-points.pdf"
  },
  {
   "for": "open research",
   "source": "https://herantis.com/wp-content/uploads/2020/04/ABG_Impressions_from_capital_markets_day_2020-03-25.pdf"
  },
  {
   "for": "open research",
   "source": "https://herantis.com/wp-content/uploads/2020/02/ABG_Herantis_Initiation_2020-02-04.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.fi-cm-kg.ai/record/FSME/FI4000087861"
  }
 ],
 "title": "Herantis Pharma Oyj (FI4000087861) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}